ArticleCancers2019

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Koichi Saruwatari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.